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Abstract
Alexus S. Williams. The impact of protein tyrosine phosphatase 1B on impaired insulin signaling
and cognitive impairment. (Under direction of Catrina Robinson)
High-fat diet (HFD) in mice, a mouse model of diet-induced obesity, display cognitive
deficits, which correlate with hyperinsulinemia and reduced levels of brain insulin. The binding
of insulin to the insulin receptor leads to tyrosine auto-phosphorylation of the receptor, which is
a necessary step for the initiation of insulin transport. Protein tyrosine phosphatase 1B (PTP1B)
dephosphorylates tyrosine residues on the Insulin receptor. We hypothesize that diet-induced
increases in PTP1B levels inhibits insulin receptor signaling contributing to cognitive
impairment. To accomplish this, PTP1B levels, tyrosine phosphorylation, and cognition was
assessed in mice placed on either a standard diet (STD) or HFD for 12-24 weeks of diet treated
with either saline (control) or Claramine (10-180g), a specific and selective PTP1B inhibitor.
After 12 weeks of diet, PTP1B levels were increased in HFD mice compared to STD mice. A
single intraperitoneal dose of Claramine (180g) reduced PTP1B levels and increased tyrosine
phosphorylation of the Insulin receptor in the hippocampus. HFD mice display cognitive deficits
using a problem-solving task, the Puzzle Box; however, Claramine treatment delivered via mini
osmotic pumps, improved cognitive deficits in HFD mice compared to STD mice. Postmortem
hippocampal tissue analysis revealed no significant differences in PTP1B levels nor the expected
increase in tyrosine phosphorylation in HFD mice treated with Claramine. Given that the
hippocampus contains multiple cell types, we investigated the impact of hyperinsulinemia, to
mimic HFD in vitro, on PTP1B, tyrosine phosphorylation of the Insulin receptor, and
downstream insulin signaling in primary brain endothelial cells, one of the main cell types
involved in mediating Insulin receptor transport from the periphery to the brain.

vii

PTP1B levels are increased in hyperinsulinemic cells and reduced in hyperinsulinemic cells
treated with Claramine. While there are no significant differences in tyrosine phosphorylation
there is a trending decrease in hyperinsulinemic cells with trending increase in hyperinsulinemic
cells treated with Claramine. Overall, our data demonstrates that Claramine is an effective
inhibitor of PTP1B in vivo and in primary endothelial cells and can improve diet-induced
cognitive deficits; however, additional studies are warranted.

viii

1.0 Introduction
1.1 Obesity and cognitive impairment
Obesity impacts more than 90 million adults in the US and more than 1 billion adults
worldwide and is a risk factor for several health-related issues including diabetes, cardiovascular
disease, and cognitive impairment [1, 2]. Obesity works in parallel with these metabolic
disorders to drive cognitive decline. The western diet or HFD is known to consist of an increase
in sugar and fat and is high in processed foods. These foods can lead to insulin resistance and
inflammation of adipose tissue, resulting in the development of obesity [3, 4]. Research shows
that individuals, who are categorized as obese are metabolically unhealthy and experience
cognitive decline faster when compared to individuals without metabolic abnormalities [5].
Lowered cognitive performance is associated with obesity according to the results of global
cognitive function tests, the Mini- Mental state examination and the Blessed InformationMemory-Concentration (IMC) test [6]. Although elevated body mass indexes (BMIs) are
associated with lowered cognitive performance, evaluating obesity using only BMI may not
indicate obesity-induced cognitive dysfunctions [6, 7]. Clinical studies using these tests have
produced varied results based on the design of the studies. Therefore, the results of preclinical
studies provide a more in-depth understanding behind the potential mechanisms of obesityrelated cognitive dysfunctions.
1.2 High-fat diet-induced obesity in preclinical models
Several studies have linked metabolic abnormalities in the B6 mouse fed ad libitum with a
HFD to those seen in human obesity patterns [8, 9]. These mice have developed obesity,
hyperglycemia, hyperinsulinemia, and hypertension, compared to mice fed a standard chow diet
(STD) [9, 10]. The HFD for animals consist of 40% more calories from fat than the STD. Diet-
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induced obesity is associated with insulin sensitivity and has demonstrated to be related to lowgrade inflammation [11]. Depending on the percentage of fat used in the HFD, studies revealed
several comorbidities such as hypertension, hyperinsulinemia and hyperglycemia [12-14].
Studies demonstrate that mice placed on a HFD display cognitive impairments 3-14 days
after starting the diet [15-18]. The HFD vs. STD mouse model is translatable in the clinical sense
as it has been connected to cardiovascular disease, chronic kidney disease and diminished insulin
signaling [19, 20]. Just as clinical studies, preclinical studies have differences in the cognitive
testing used to assess these cognitive impairments. Several studies using working, spatial and
recognition memory have demonstrated reduced cognitive performance in animals of dietinduced obesity [15, 21-24].
1.3 Hyperinsulinemia and insulin resistance
Diet-induced obesity is known to disrupt the blood brain barrier, limiting the ability of the
insulin receptor to mediate the transport of insulin into the central nervous system (CNS),
leading to hyperinsulinemia and Insulin receptor resistance [25, 26]. Insulin resistance is a
reduced responsiveness of a cell or organism to insulin [27]. HFD treated rodents produce
metabolic syndromes including type 2 diabetes, cardiovascular disease, peripheral
hyperinsulinemia, and insulin resistance [26, 27]. Although insulin resistance is typically
accompanied by hyperinsulinemia, many scientists suggest that hyperinsulinemia is
compensation for insulin resistance, while others report that hyperinsulinemia produces insulin
resistance [28-31]. Hyperinsulinemia and insulin resistance are the result of endothelial
dysfunction caused by reductions in phosphoinositide 3 kinase (PI3K) signaling that leads to a
decrease in nitric oxide (NO) production [32, 33].
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1.4 Insulin receptor signaling and receptor phosphorylation

Figure 1: Insulin receptor signaling pathway.
Modified from: Yang, Z., et al., A novel PTP1B
inhibitor extracted from Ganoderma
lucidum ameliorates insulin resistance by
regulating IRS1-GLUT4 cascades in the
insulin signaling pathway. Food Funct,
2018. 9(1): p. 397-406.

Cellular action of insulin is induced by the binding of insulin to the alpha subunit of the
Insulin receptor (Fig.1) [34, 35]. Phosphorylation of proteins require activity of phosphatases and
protein kinases whereas the phosphate groups are removed by phosphatases and the protein
kinases attach phosphate groups from ATP to serine, threonine or tyrosine residues [36]. The
binding of insulin to its receptor leads to a conformational change where the tyrosine residues
located on the beta subunits, including Tyr 1150 and 1151 are auto phosphorylated as well as
phosphorylation of tyrosine residues on insulin receptor substrates (IRS 1-3) [37-39]. Before
insulin receptor activation occurs, IRS-1 is heavily serine and threonine phosphorylated,
inhibiting tyrosine phosphorylation [38, 40]. An activated insulin receptor drives
phosphorylation of several protein substrates that are important for downstream metabolic
insulin receptor signaling including PI3K [37]. PI3K activation then phosphorylates
phosphoinositide substrates needed for activation of PI3K dependent kinase 1 (PDK1), which is
important for the activation of protein kinase B (AKT)[37]. AKT plays a key role in insulin
signaling being that its interaction at the membrane allows for the phosphorylation of two other
protein kinases that phosphorylate AKT (pAKT) at Threonine 208 and Serine 473. The
3

phosphorylation of AKT leads to an increase in GLUT4 (glucose transporter type 4) transporters
at the cell surface therefore increasing peripheral glucose uptake. [41-43]. AKT regulates many
target proteins of the insulin signaling pathway such as transcription factor FOX01 (forkhead
box protein 01) and is essential for glucose and glycogen transport and metabolism and GSK3 (
glycogen synthase kinase 3 beta) as it is phosphorylated by AKT and inactivated allowing
glycogen synthesis lowering glucose levels in the blood [34, 43, 44].
The phosphorylation and dephosphorylation of proteins involve two enzymes: kinases and
phosphatases. The adding of a phosphate group to a protein involves kinases whereas the
removal of phosphate groups phosphatases. Protein phosphatases are classified by the specific
substrates they interact with such as threonine, serine, and tyrosine substrates. There are
structural families of protein phosphatases including the serine/ threonine protein phosphatase
consisting of the PP1,PP2A and PP2B enzymes and the protein tyrosine phosphatase (PTP)
family, specific for phosphotyrosine containing proteins[45]. The removal of phosphate groups
from tyrosine residues on the insulin receptor is a key step in negative regulation of the insulin
receptor [46, 47]. Cellular insulin signaling impairment results in a reduction of the active
intracellular insulin signaling cascade via increased phosphatase expression such as PTP1B, that
removes phosphorylated tyrosine residues [34].
1.4.1

PTP1B and inhibitors

Phosphatases, for most signaling pathways, are a crucial event as they remove the phosphate
groups from phosphorylated tyrosine residues [37]. PTP1B has been established as an important
enzyme in the inactivation of the insulin receptor including downstream signaling of IRS-1 by
removing tyrosine phosphate from the insulin receptor [46]. PTP1B is an intracellular protein
tyrosine phosphatase which is located on the endoplasmic reticulum with the phosphate domain
4

positioned toward the cytoplasm and is expressed in typical insulin selective tissues like muscle,
fat and the liver [37]. Overexpression of PTP1B had been shown to inhibit signaling events and
also has been known to be a target for anti-obesity and anti-diabetic therapies due to its
association with insulin resistance, obesity, and diabetes [37]. Studies have shown that mice
deficient of PTP1B displayed increased insulin receptor and IRS-1 phosphorylation, were more
resistant to weight gain even when placed on a HFD when compared to wild type mice and were
sensitive to insulin [37, 46, 48]. When deleted in the CNS of mice, mice were resistant to
diabetes as well, leading to determining the importance of PTP1B inhibition in the central and
peripheral control of insulin signaling [43, 49].
PTP1B is associated with several diseases leading to the development of potent and specific
inhibitors to treat cardiovascular disease, obesity, cancers, and diabetes [50]. PTP1B inhibitors
specific for diabetes and obesity that had entered clinical trials include JTT-555 [51], ertiprotafib
[37], and Trodusquemine (MSI-1436) [52]. Studies on Trodusquemine has been important for
weight reduction, and anti-obesity therapies [52]. Claramine is a synthesized analog of a highly
selective inhibitor of PTP1B, Trodusquemine. Claramine has been found to inhibit PTP1B
activity and improve insulin sensitivity, while not effecting closely related phosphatases like TCPTP. Claramine has demonstrated the ability to activate phosphorylation of the insulin response
cascade including InsR- and AKT which needed for the monitoring of glucose in neuronal cells
[43]. Studies have displayed that Claramine, when administered in a single intraperitoneal dose,
can suppress the feeding behaviors of mice, concluding that Claramine can navigate across the
blood brain barrier (BBB) [43].
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1.5 Cognitive assessments in animals
Cognitive assessments in animals pertain to assessing deficits in processes such as attention,
memory, and problem-solving [53]. Attention is a cognitive skill that depends highly on
executive function and mental flexibility and is normally assessed using reversal learning tasks
where the learning strategies of the animal is forced to be altered requiring attention and
cognitive flexibility [54]. Studies assessing memory has been focused on assessing memory with
aging, as one of the most common cognitive functions leading to cognitive decline [53].
Impairments of memory often consists of working, declarative/episodic or spatial memory.
Declarative/episodic memory depends on remembering, in a spatial context and is also most
affected by aging [55]. Working memory is defined as the short term storage of information by
the animals [56]. Working memory in humans is closely related to attention, long-term memory,
and motor processes[57-59]. Like humans, animals can sustain information in working memory
but can only do so without interference[60]. The concept of spatial memory is that it is
hippocampal dependent, in humans spatial memory is assessed in patients that have hippocampal
damage whereas in animals, task are completed that require hippocampal function [61, 62].
Some common working and spatial memory task include the T- maze [63], the radial arm maze
[64], the Morris water maze [65] as well as recognition and localization task Novel object
recognition [15, 66] and Novel object location [67, 68]. The ability to problem solve is defined
as creating new behaviors using pre-existing behaviors in new contexts [69]. The Puzzle Box is a
problem- solving task that has demonstrated effectiveness when detecting cognitive deficits [7072]. The Puzzle box task has been used as a cognitive rehabilitation task for mice revealing
enhancement of performance when repeating the task [72].
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The purpose of this study is to show that with HFD and obesity there is a risk of
hyperinsulinemia and insulin resistance. The impact of hyperinsulinemia and insulin resistance
can lead to cognitive impairment due to the decrease of insulin transport and uptake through the
BBB. Our overall question is: what is the mechanism that occur in obesity that effect cognitive
impairments? We chose to focus on hyperinsulinemia and insulin resistance and its negative
impact it has on brain health. We have background supporting the connection between obesity
and PTP1B and its negative effects on insulin receptor phosphorylation, we further investigate
the effects of inhibiting PTP1B to improve insulin sensitivity and cognitive impairments.
Our overall hypothesis is diet induced increases in PTP1B levels inhibits insulin receptor
signaling contributing to cognitive impairments. To examine our hypothesis, this project
investigated 2 specific aims:
Aim 1: test the hypothesis that the inhibition of PTP1B rescues diet induced cognitive
deficits. In this aim we used male C57BL6 mice separated into two group (STD and HFD) and
assessed cognitive deficits pre and post the implantation of mini-osmotic pumps containing
Claramine. Tissue collected post assessments were processed to assess insulin signaling, tyrosine
phosphorylation and PTP1B levels.
Aim2: test the hypothesis that hyperinsulinemia increases PTP1B levels in endothelial cells.
In this aim we used primary C57BL6 mouse brain endothelial cells treated to be non
hyperinsulinemic, hyperinsulinemic, and hyperinsulinemic with Claramine inhibition. Post
treatment cells were taken up and processed to assess insulin signaling, tyrosine phosphorylation
and PTP1B levels.
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Results of this study supports the evidence that hyperinsulinemia occurring from dietinduced obesity is associated with cognitive deficits as well as deficits in insulin signaling.
Understanding of the effects of PTP1B on insulin signaling and cognitive impairment allows for
additional research on insulin transport and receptor internalization.

2.0 Materials and methods
2.1 Animal model
Male C57BL6 mice (Jackson Laboratory, Bar Harbor, Maine) were placed on either a
standard, control diet that consists of 10% kcal from fat (STD; Research Diets Inc.; D12450B
New Brunswick, NJ) or a HFD that consists of 54% kcal from fat (Research Diets Inc.;
D05090701). Both diets were started at 6 weeks of age.
Mice are housed in a pathogen- free environment. All protocols were approved by the
Medical University of South Carolina Institutional Animal Care and Use Committee and are in
compliance with the university guideline, state and federal regulations, and the standard of the
“Guide for Care and Use of Laboratory Animals”. Animal Welfare Assurance Number on file
with the NIH Office of Laboratory Animal Welfare (OLAW) is A3428-01 (Medical University
of South Carolina is accredited by the Association for the Assessment and Accreditation of
Laboratory Animal Care International (AAALAC, Intl.).

2.2 Claramine Administration
2.2.1 Intranasal Claramine Administration
Claramine trifluoroacetate (SML1545, Sigma-Aldrich) was intranasally (IN) administered
to mice at 12 weeks of age via micropipette. Mice were placed on either a STD or HFD. Mice were
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anesthetized with isoflurane and one group received a Claramine dosing volume of 12 l of
concentrations of 10 µg, 100 µg, 180 µg Claramine as the second group received saline as a control
(n= 4 per group). Animals were randomly assigned to insulin concentration groups based on cage
number. 1-hour post IN administration, mice were euthanized with isoflurane overdose and cardiac
perfused with 1X Phosphate-Buffered solution (PBS). Brain dissection was completed collecting
the hypothalamus, right and left hippo, cortex, and cerebellum. Sections were collected and
processed for protein analysis and western blotting.
2.2.2 Intraperitoneal Claramine Administration
Claramine trifluoroacetate (SML1545, Sigma-Aldrich) was intraperitoneally (IP)
administered to mice at 12 weeks of age. Mice were placed on either a STD or HFD. Mice were
anesthetized with isoflurane and one group receives Claramine dosing volume of 200 l of
concentrations of 10 µg, 100 µg, 180 µg as the second group received saline as a control (n= 4 per
group). Animals were randomly assigned to treatment groups based on cage number. 1-hour post
IN administration, mice were euthanized with isoflurane overdose and cardiac perfused with 1X
Phosphate-Buffered solution (PBS). Brain dissection was completed collecting the hypothalamus,
right and left hippo, cortex, and cerebellum. Sections were collected and processed for protein
analysis and western blotting.
2.2.3 Mini-osmotic pump implantation and Claramine administration
Mini-osmotic pumps (ALZET® osmotic pump; model 1002) contained either sterile
saline or Claramine. Over a period of 10 days, STD mice (28 weeks old, n= 8) and HFD mice
(26 weeks old, n= 7) received 6 l per day of Claramine at a concentration of 10 g/day. Control
groups, STD mice (29 weeks old, n= 7) and HFD mice (27 weeks old, n= 6) received sterile
saline. Preparation of the mini osmotic pumps was completed as described by the manufacturer
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for the specific model. The pumps were weighed before and after filling with either saline or
Claramine. The filled pumps were incubated in sterile saline overnight to ensure priming for
implantation. For implantation, one the animal was anesthetized, the implant site was shaved and
cleaned. A skin incision was made at the midline in the lower abdomen. The sterile filled pump
was inserted into the peritoneal cavity flow moderator first. The incision was then closed using
absorbable sutures and mice are allowed to recover for 48 hours
2.3 Cognitive assessments in mice
2.3.1 Puzzle box
The puzzle box is a problem-solving task that can be used to assess cognitive deficits (see
appendix)[72]. The puzzle box is separated into two parts, an open field where the mouse is placed
at the beginning of the task, and a dark field, where the mouse must escape to end the task (Fig.1A).
The open door is unblocked and used as a form of habituation to let animals get acclimated to the
box. Four different obstacles are placed In front of the open door (Fig. 1B) to obstruct the escape
door, each adding complexity: (1) the nestlet, is used by the mice to shred as bedding in their
home cages, its placement behind the door allows it to act as a doggy door (Fig 1C); (2) envirodri, is placed in front of the door so mice have to burrow through or pull away from the door to
escape (Fig 1D); and (3) the tunnel is a t- shaped tunnel giving the mouse three ways to enter the
dark side (Fig. 1E). At the start of every trial of the task, recording is done using a camera mounted
above the open field. The camera was started, and recordings was used for later analysis. Each
animal completed three trials per obstacle allowing for a clear view of data and to determine if
there was an enhancement of performance. This task was completed before and after mini pump
implantation.
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A

B
C
D

Figure 2: Puzzle box design and obstacles. (A)
The top view of the puzzle box arena. The
puzzle box consists of an open field (*)
connected by an (B) open door (black arrow) to
a dark box (◊). The open door zone (red box) is
obstructed with either (C) the nestlet, (D)
enviro-dri, or (G) a tunnel.

E

2.3.2 Novel Object Recognition task (NOR)
The NOR task (Fig. 2) was done in a circular, open field. On the first day the mice were
subjected to habituation, where they were allowed to explore the empty arena three times for 10
minutes. On the second day, the exploration phase, the mice were placed in the arena with two
identical objects located on opposite ends of the arena and allowed to explore those objects for 10
minutes before being placed back in their home cages (Fig. 2A). Following about a 30-45 min
delay, the mice were returned to the arena with one object identical to the objects used in the
exploration phase and a second object that is novel, located on the opposite end of the arena (Fig.
2B). The mice were allowed to explore these objects for 10 minutes. The objects that were used
for this task was a j-hook and a raft. Both the arena and objects were cleaned thoroughly with 70%
ethanol each time before a different mouse was allowed into the arena. A camera mounted above
the open field was used for recording and mouse tracking for later analysis. Data such as
exploration of the novel object, familiar object, and total exploration was collected. Percentage of
novel object exploration was calculated using this formula, B/ A+B * 100.
11

A

B

Exploration

Novel
A

B

Figure 3: Novel Object Recognition
(NOR) task. The top view of the
NOR arena. (A). Exploration phase
with identical objects on opposite
ends of arena. (B) Novel phase, one
object is replaced with a novel object
on the opposite end of the arena.

2.3.3 Novel Object Location task (NOL)
The NOL task is completed with similar set up as the NOR task. The first day the mice
were habituated to the arena for 10 minutes. On the second day the mice were placed in the arena
with two different objects similar the set-up of the novel phase of the NOR task, as the exploration
phase for NOL and allowed to explore the objects for 10 minutes. Following a delay, the mice
were placed back into the arena with the same objects but the location of one of the objects was
moved. The mice were allowed to explore the objects with the location change for 10 minutes
before being placed back in their home cages. The objects that were used for this task was a j-hook
and a raft as well. Both the arena and objects were cleaned thoroughly with 70% ethanol each time
before a different mouse was allowed into the arena. A camera mounted above the open field was
used for recording and mouse tracking for later analysis. Data such as time spent exploring the
object moved to a novel place, the object remaining in the familiar place, and total time spent in
exploration of objects were calculated. Reference memory was calculated using the formula, C/
(A+C) *100. Total memory was calculated using the formula, (A+C)/ (A+B+C) *100.

A

Exploration

B

Novel
B

A
C

Figure 4: Novel Object Location
(NOL) task. The top view of the NOL
arena. (A). Exploration phase with two
different objects on opposite ends of
arena. (B) Novel phase, right object has
a location change and is moved to the
back of the arena.
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2.4 Tissue preparation
The mice were anesthetized with isoflurane and euthanized with an overdose of 1X PBS.
Brains were dissected collecting the right and left cortex, right and left hippocampus, left and
right cerebellum, the hypothalamus and liver. These samples were placed in separate tubes,
frozen in liquid nitrogen, and stored at -80°C until use for lysate preparation.
2.5 Lysate preparation
Hippocampal tissue samples were homogenized in a microcentrifuge tube with T-PERTM
(Tissue Protein Extraction Reagent; Thermo Scientific, VH311203) + protease inhibitor
(complete mini EDTA free; Roche Diagnostics, 11836170001) then analyzed using the Pierce
Protein Assay ( 660nm Protein assay reagent ; Thermo Scientific, WB319801) for protein
concentration quantification for equal sample concentration assurance. Sodium dodecyl sulfate
(SDS) was added to the samples to make the lysates for polyacrylamide electrophoresis and
western blot analysis.

2.6 Primary Cell Culture
Primary C57BL/6 mouse brain microvascular endothelial cells (MBECs; C57-6023, Cell
Biologics, Chicago, IL) were seeded in 12-well plates and coated with rat tail collagen type I
(A1048301, Gibco, Waltham, MA) for cell experiments and allowed to grow to 80-90%
confluency before treatment began. Cells were grown in Complete Mouse Endothelial Cell
Medium with supplemental kit (M1168 + kit, Cell Biologics), at 37°C in 5% CO 2. All experiments
were completed on passage 5 cells.
Insulin stimulation and Claramine treatments were done at 37°C. Hyperinsulinemic
conditioning was induced in MBECs by incubating cells for 12 hours in 20nM human recombinant
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insulin (I9278, Sigma, St. Louis, MO). 30 minutes before the end of the 12 hours, MBEC’s were
incubated with for 30 minutes in 50nM Claramine trifluoroacetate (SML1545, Sigma-Aldrich). At
the end of the 12 hours insulin stimulation was done, which is essential when assessing insulin
signaling. The insulin stimulation is done by incubating cells in 20nM insulin for 15 minutes.
Insulin and Claramine were diluted directly into culture media. Before treatment cells were washed
for 30 min with warm 1x PBS solution (Corning™ Mediatech™, Tewksbury, MA) and replaced
with fresh media. Post treatment, media was removed and supplanted with T-PER (Thermo
Scientific™, Waltham, MA) + protease inhibitor (Roche), scraped, and stored at -80°C until
analysis.
2.7 Western immunoblotting
Western immunoblotting was performed using tissue lysate samples and cell lysate samples.
Lysates were separated by SDS-PAGE and transferred to a nitrocellulose membrane. TBS with
Tween-20 supplemented with 5% BSA was used to block the membranes and to dilute the
antibodies. Polyclonal antibodies against protein kinase B (AKT), insulin receptor beta (InsR-β),
phosphorylated insulin receptor at tyrosine residues 1150/1151 (pInsRY1150/1151); all from Cell
Signaling Technology, were used at a 1:1000 dilution. Phosphorylated AKT at serine residue 473
(pAKTS473; Cell Signaling Technology) was used at a 1:2000 dilution. TBS with Tween-20
supplemented with 5% milk was used to block membranes with polyclonal antibodies against
PTP1B (Anti-PTP1B antibody; abcam) and to dilute antibodies at a 1:2000 dilution. The
appropriate horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology)
was used at a 1:2000 dilution. Protein signal quantification was visualized using Clarity Western
ECL Substrate (Bio-Rad Laboratory, Hercules, CA), with images captured using ChemiDocTM
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Imaging System, analyzed by Image Lab software (Bio-Rad Laboratory), and normalized to total
lane protein concentrations.
2.8 Statistical analysis
2.8.1

Animal statistical analysis

Data analyses were performed using Prism v6 (GraphPad Software, Inc.). All sample sizes
represent the number of animals. All data were analyzed using either a one- way ANOVA with
Tukey’s Multiple Comparison Test ( IP Claramine administration, IN Claramine Administration,
assessing memory deficits in mice using the novel object recognition task and assessing memory
deficits in mice using the novel object location task), a two- way ANOVA with Tukey’s Multiple
Comparison Test (insulin signaling and PTP1B levels following IP Claramine administration and
insulin signaling and PTP1B levels following mini- osmotic pump Claramine administration), or
a mixed- effects repeated measures analysis with Tukey’s Multiple Comparisons test (assessing
problem solving deficits in mice). All data represents as mean ± standard error of the mean. All
analysis significance was determines using an alpha-level of 0.05.

2.8.2 Primary cell culture statistical analysis
Data analyses were performed using Prism v6 (GraphPad Software, Inc.). All data were
analyzed using a two- tailed t-test, normalized to naïve cells (1.00). All data represents as mean ±
standard error of the mean. All analysis significance was determines using an alpha-level of 0.05.
Cell culture sample sizes represent the number of total biological replicates (n).
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3.0 Results
3.1 Intraperitoneal Claramine administration
We sought to investigate PTP1B levels after 1 hour in hippocampal tissue from STD and
HFD mice (n=4/group) after 12 weeks of diet given a single 1P injection of either saline or
Claramine (10,100 or 180 µg) (Fig. 4; F= 3.574). In hippocampal tissue, PTP1B levels increased
in HFD mice given a single IP injection saline (6.170± 2.023) by 568.6% from STD mice given a
single IP injection saline (0.9228± 0.08625). When given HFD mice a single IP injection of
Claramine, hippocampal PTP1B levels were not significantly different when receiving the 10µg
Claramine dose (4.204± 0.1164) or when receiving the 100µg Claramine dose (3.052± 1.355) but
decreased by 72.2% when receiving the 180µg Claramine dose (1.713± 0.2869) when compared
to HFD mice given a single IP injection of saline (6.170± 2.023).
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Figure 5: Intraperitoneal (IP) Claramine
administration. Protein expression of
hippocampal protein tyrosine phosphatase 1B
(PTP1B) in mice on either a standard diet
(STD) or high-fat diet (HFD) for 12 weeks
followed by IP administration of either saline or
Claramine (10, 100, 180 µg) Data represent
mean ± standard error of the mean (SEM).
*P<0.05 based on one-way ANOVA with
Tukey’s multiple comparisons test; n= 4/ group.

Claramine (g)

3.2 Intranasal Claramine administration
We sought to investigate PTP1B levels after 1 hour in hippocampal tissue from STD and
HFD mice (n=4/group) after 12 weeks of diet given intranasal saline or Claramine (10,100 or
180 µg) dose (Fig. 5; F=3.037). In hippocampal tissue, PTP1B levels increased in HFD mice
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given intranasal saline (6.354± 0.5907) by 167.9% from STD mice given intranasal saline
(0.2372± 0.3650). When giving HFD mice intranasal Claramine, hippocampal PTP1B levels
were not significantly different when receiving the 10µg Claramine 0.3779± 0.09912), the 100µg
Claramine (0.4402± 0.1002) or the 180µg Claramine (0.4391± 0.06277) when compared to HFD
mice treated with intranasal saline (0.6354± 0.05907).
Figure 6: Intranasal (IN) Claramine
administration. Protein expression of
hippocampal protein tyrosine phosphatase 1B
(PTP1B) in mice on either a standard diet (STD)
or high-fat diet (HFD) for 12 weeks followed by
IN administration of either saline or Claramine
(10, 100, 180 µg). Data represent mean ±
standard error of the mean (SEM). *P<0.05
based on one-way ANOVA with Tukey’s
multiple comparisons test; n= 4/ group.

3.3 Insulin signaling and PTP1B levels following IP Claramine administration
The basal protein levels of hippocampal pAKT/AKT (Fig. 6A; F=2.822), pInsR-β
Y1150/1151/total InsR-β (Fig. 6B; F=70.27) and PTP1B (Fig. 6C; F=13.14) were evaluated to
assess insulin signaling and PTP1B levels in STD and HFD mice (n=4/group) after 12 weeks of
diet and 1 hour after IP saline or Claramine (180 µg). In STD mice treated with Claramine
(0.049± 0.011), hippocampal pAKT decreased by 60.5% compared to STD mice treated with
saline (0.124± 0.019). In HFD mice treated with Claramine (0.054± 0.013), hippocampal pAKT
was not significantly different compared to HFD mice treated with saline (0.078± 0.016).
STD mice treated with Claramine (2.281± 0.127), hippocampal phosphorylated tyrosine
residues on InsR-β decreased by 80.0% compared to STD treated with saline (11.414± 1.371).
HFD mice treated with Claramine (8.859± 0.359), hippocampal phosphorylated tyrosine residues
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on InsR-β increased by 83.5% compared to HFD mice treated with saline (4.828± 0.355). HFD
mice treated with saline (4.828± 0.355), hippocampal phosphorylated tyrosine residues on InsRβ decreased by 57.7% compared to STD treated with saline (11.414± 1.371).
STD mice treated with Claramine (4.428± 0.219), there were no significant differences from
STD mice treated with saline (1.433± 0.079). HFD mice treated with saline (6.170± 2.023)
hippocampal PTP1B levels increased by 330.6% compared to STD mice treated with saline
(1.433± 0.079). HFD mice treated with Claramine (1.713± 0.287), hippocampal PTP1B levels
Saline2.023).
Claramine
decreased by 260.3% compared to HFD mice treated with saline (6.170±
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Figure 7: Insulin signaling and PTP1B levels following IP Claramine administration. (A)
Protein expression of hippocampal pAKT/AKT (B) Protein expression of hippocampal pInsR-β
Y1150/1151/total InsR-β (C) Protein expression of PTP1B in mice on either a standard diet
(STD) or high-fat diet (HFD) for 12 weeks followed by IP administration of either saline or
Claramine (180 µg). Data represent mean ± standard error of the mean (SEM). *P<0.05,
***P<0.001, ****P<0.0001 based on two-way ANOVA with Tukey’s multiple comparisons test;
n= 4/ group.
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3.4 Assessing problem- solving deficits in mice using the puzzle box task
Escape latencies in STD and HFD mice after 21 weeks of diet, were analyzed following
mini- osmotic pump implantation administering saline or Claramine (Fig. 7; F=4.546). There
were no significant differences in open door escape latencies between STD mice treated with
saline (n=7; 12.017± 2.565), HFD treated with saline (n=6; 21.418± 6.190), STD mice treated
with Claramine (n=8; 46.113± 23.089) and HFD mice treated with Claramine (n=7; 45.257±
18.644). In a more complex obstacle, the tunnel, escape latencies of HFD mice treated with
saline (223.117± 29.838) increased by 117.3% compared to escape latencies of STD mice treated
with saline (102.657± 31.718). Last, there were no significant differences in escape latencies of
the tunnel obstacle between STD mice treated with Claramine (123.150± 36.293) and HFD mice
treated with Claramine (141.100± 40.707).
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HFD
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Figure 8: Assessing problem- solving
deficits in mice. The escape latency
(seconds; sec) for the open-door and
tunnel in mice on a standard diet (STD;
white and light grey bars) or high-fat diet
(HFD; black and dark grey bars) for 21
weeks followed by administration of either
saline or Claramine via mini-osmotic
pump implant. Data represents mean ±
SEM; n=7 (STD-saline), n=6 (HFDsaline), n=8 (STD-Claramine) and n=7
(HFD-Claramine); *P≤ 0.05. A mixedeffects repeated measures analysis with
Tukey’s multiple comparisons test.

3.5 Assessing memory deficits in mice using the novel object recognition task
Percent exploration time of the novel object using the NOR task in STD and HFD mice
after 21 weeks of diet before the mini-osmotic pump implant (baseline) and post implant treated
with saline or Claramine (Fig. 8; F=2.391). There were no significant differences in the percent
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exploration of the novel object between STD baseline mice (n=15; 43.158± 4.655), HFD
baseline mice (n=13; 34.137± 2.654), STD mice treated with saline (n=7; 51.427±6.314), HFD
mice treated with saline (n=6; 46.658± 8.333), STD mice treated with Claramine (n=8; 53.679±
5.391) and HFD mice treated with Claramine (n=7; 52.932± 5.932).

Figure 9: Assessing memory deficits in mice using the novel object recognition
(NOR) task. The percent exploration time of the novel object in mice on a standard
diet (STD; white bars) or high-fat diet (HFD; black bars) for 21 weeks (baseline)
followed by administration of either saline or Claramine via mini-osmotic pump
implant. Data represents mean ± SEM; n=15 (STD baseline), n=13 (HFD baseline),
n=7 (STD-saline), n=6 (HFD-saline), n=8 (STD-Claramine) and n=7 (HFDClaramine). Based on one-way ANOVA with Tukey’s multiple comparisons test.
3.6 Assessing memory deficits in mice using the novel object location task
Percent reference memory of the NOL was calculated in STD and HFD mice after 21
weeks of diet before the mini-osmotic pump implant (baseline) and post implant treated with
saline or Claramine (Fig. 9A; F=0.8731). There were no significant differences in the percent
exploration of the novel object between STD baseline mice (n=15; 67.090± 4.850), HFD
baseline mice (n=11; 58.505± 5.233), STD mice treated with saline (n=7; 64.525± 8.260), HFD
mice treated with saline (n=6; 50.322± 7.323), STD mice treated with Claramine (n=8; 58.755±
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6.861) and HFD mice treated with Claramine (n=7; 60.974± 4.222). Percent Total memory of the
NOL was calculated in the same mice. (Fig. 9B; F=0.7831). There were no significant
differences in the percent exploration of the novel object between STD baseline mice (n=15;
81.211± 2.643), HFD baseline mice (n=11; 73.658± 4.005), STD mice treated with saline (n=7;
79.308± 4.911), HFD mice treated with saline (n=6; 74.107± 4.191), STD mice treated with
Claramine (n=8; 73.102± 6.082) and HFD mice treated with Claramine (n=7; 76.013± 3.564).
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Figure 10: Assessing memory deficits in mice using the novel object location (NOL) task. (A)
The percent reference memory and (B) percent total memory in mice on a standard diet (STD;
white bars) or high-fat diet (HFD; black bars) for 21 weeks (baseline) followed by administration
of either saline or Claramine via mini-osmotic pump implant. Data represents mean ± SEM; n=15
(STD baseline), n=11 (HFD baseline), n=7 (STD-saline), n=6 (HFD-saline), n=8 (STD-Claramine)
and n=7 (HFD-Claramine). Based on one-way ANOVA with Tukey’s multiple comparisons test.

3.7 Insulin signaling and PTP1B levels following mini- osmotic pump Claramine
administration
The basal protein levels of hippocampal pAKT/AKT (Fig. 10A; F=0.07019), pInsR-β
Y1150/1151/total InsR-β (Fig. 10B; F=18.69) and PTP1B (Fig. 10C; F=1.060) were evaluated to
assess insulin signaling and PTP1B levels in STD and HFD mice after 21 weeks of diet
following mini- osmotic pump implantation administering saline or Claramine. There were no
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significant differences in hippocampal pAKT levels between STD mice treated with saline (n=7;
0.078± 0.014), HFD mice treated with saline (n=6; 0.079± 0.007), STD mice treated with
Claramine (n=8; 0.062± 0.006) and HFD mice treated with Claramine (n=7; 0.070± 0.020).
When assessing hippocampal phosphorylated tyrosine residues on InsR-β there was a
138.9% increase in STD mice treated with Claramine (n=8; 2.951± 0.327) when compared to
STD mice treated with saline (n=7; 1.235± 0.296). There were no significant differences in HFD
mice treated with saline (n=6; 1.632± 0.257) and HFD mice treated with Claramine (n=6; 0.887±
0.159). In HFD mice treated with Claramine (0.887± 0.159) there was a 69.9% decrease of
phosphorylated tyrosine residues on InsR-β when compared to STD mice treated with Claramine
(2.951± 0.327). When assessing basal hippocampal PTP1B levels there were no significant
differences between STD mice treated with saline (n=7; 4.823± 1.210), HFD mice treated with
saline (n=6; 3.989± 0.972), STD mice treated with Claramine (n=8; 3.748± 0.859) and HFD
mice treated with Claramine (n=7; 5.152± 1.247).
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Figure 11: Insulin signaling and PTP1B levels following mini-osmotic pump Claramine
administration. (A) Protein expression of hippocampal pAKT/AKT (B) Protein expression of
hippocampal pInsR-β Y1150/1151/total InsR-β (C) Protein expression of PTP1B in mice on
either a standard diet (STD) or high-fat diet (HFD) for 21 weeks followed by administration of
either saline or Claramine via mini-osmotic pump implant. Data represent mean ± standard error
of the mean (SEM). ***P<0.001 based on two-way ANOVA with Tukey’s multiple
comparisons test; n=7 (STD-saline), n=6 (HFD-saline), n=8 (STD-Claramine) and n=7 (HFDClaramine).

3.8 Insulin signaling and PTP1B in primary mouse brain endothelial cells
The protein levels of pAKT/AKT (Fig. 11A), pInsR-β Y1150/1151/total InsR-β (Fig.
11B) and PTP1B (Fig. 11C) were evaluated to assess insulin signaling and PTP1B levels in
primary MBEC’s (n=4) after hyperinsulinemia, Claramine and insulin stimulation treatments
(normalized to naïve cells). There is a 21.9% decrease of pAKT in cells that were
hyperinsulinemic (0.7813± 0.03887) compared to naïve cells (1.000± 0.09080). Cells that were
hyperinsulinemic, treated with Claramine and received insulin stimulation (0.8503± 0.0009009),
there was a 14.9% decrease of pAKT when compared to naïve cells. There were no significant
differences between naïve cells and cells that were non-hyperinsulinemic with insulin
stimulation (0.8729±0.4809), non-hyperinsulinemic treated with Claramine and insulin
stimulation (0.4809± 0.1806) and hyperinsulinemic with insulin stimulation (1.072± 0.5130).
There were no significant differences in phosphorylated tyrosine residues on InsR-β in
cells that were hyperinsulinemic (1.255± 0.7771), non-hyperinsulinemic with insulin stimulation
(0.7792± 0.02057), non-hyperinsulinemic treated with Claramine with insulin stimulation
(0.7590± 0.005740), hyperinsulinemic with insulin stimulation (1.488± 0.4225) and
hyperinsulinemic treated with Claramine with insulin stimulation (1.245± 0.6997) when
compared to naïve cells (1.000± 0.2146).
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When assessing PTP1B levels in MBEC’s, there was an 6.8% increase of PTP1B in
hyperinsulinemic cells (1.068± 0.01098) compared to naïve cells (1.000± 0.06479). There was a
11.3% decrease of PTP1B in cells that were non- hyperinsulinemic with insulin stimulation
(0.8868± 0.0002747) compared to naïve cells. There were no significant differences in PTP1B
levels when cells were non-hyperinsulinemic treated with Claramine with insulin stimulation
(0.9614± 0.2847), hyperinsulinemic with insulin stimulation (0.7301± 0.08559) and
hyperinsulinemic treated with Claramine with insulin stimulation (0.8529± 0.2711) when
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Figure 12: Insulin signaling and PTP1B levels in primary mouse brain endothelial
cells (MBEC’s). (A) Protein expression of hippocampal pAKT/AKT (B) Protein expression
of hippocampal pInsR-β Y1150/1151/total InsR-β (C) Protein expression of PTP1B in
MBEC’s that were hyperinsulinemic (HI), non-HI+, non- HI with Claramine+, HI+ and HI
with Claramine + all normalized to naïve cells (dotted line at 1.0) .15 min insulin stimulation
(+). Data represent mean ± standard error of the mean (SEM). *P<0.05, ***P<0.001,
****P<0.0001 based on one-sample t test; n= 4

4.0 Discussion
From our study we know that the observation that a single dose of Claramine via IP
administration decreased hippocampal PTP1B levels indicating that Claramine is able to cross
the BBB, similar to its analog Trodusquemine [52]. We also show that Claramine treatment may
improve cognitive deficits in HFD mice when completing a problem-solving task. Last in our
study, we demonstrated that in MBEC’s, hyperinsulinemia increased PTP1B levels, whereas
with Claramine treatment PTP1B levels were comparable to naïve cells. Gaps between our study
and the literature could be the ability to improve insulin signaling with Claramine treatment and
the ability to successfully deliver Claramine and assess cognitive deficits with more than one
cognitive task.
There are many inhibitors of PTP1B activity, however, due to successful studies using
Trodusquemine and Claramine, we chose to use Claramine as the PTP1B inhibitor for this study.
Trodusquemine is also classified as a highly selective PTP1B inhibitor and is known for its
ability to cross the BBB and to block PTP1B activity in neuronal cells [52, 73]. It is known that
the half-life of Trodusqumine is >1 week; however, research has not concluded the half-life of its
analog, Claramine [52]. Studies done by Qin et.al. were successful in concluding that when used
in whole cell lysates in vitro, both Claramine and Trodusquemine inhibited PTP1B activity in
dosing experiments; however, when applied to intact live cells, Claramine was not effective in
inhibiting PTP1B activity [43]. This group was also successful in showing that with Claramine
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treatment, in neuronal cells, there was an increase in phosphorylation of IR and AKT, key
components of the insulin signaling cascade. In our study, we found that pAKT was decreased
with hyperinsulinemia in the MBEC’s but not increased when treated with Claramine but,
PTP1B levels were decreased with Claramine treatment of hyperinsulinemic MBECs. The
difference could be timing differences with taking up cells and processing them whereas it was a
quick process in the study described when compared to our study. Previous studies may differ
due to the difference in cell types used, whereas our study used primary mouse brain endothelial
cells which is more specific compared to neuronal cells used in other studies mentioned.
The NOR task has been commonly used to allow translation into cognitive disorders
relevant to disorders seen in humans. This task, assessing recognition memory in rodents, is
known for its rapid data generation, unchallenging operation, and its elimination of long training
procedures. In a study completed in 2016 [15], assessing dietary reversal on long-term memory
deficits concluded that when completing the NOR task after being on the diet for 2,6, and 24
weeks, control mice spent 50% more time exploring the novel object than HFD mice meaning
that cognitive deficits were present in HFD mice in as few as 2 weeks on the diet. The results of
our study showed that even at baseline, there were no differences seen between STD and HFD
mice, nor did Claramine treatment of HFD mice on the diet for 21 weeks improve performance.
Although this task is easy-to-use, some limitations can include sample size. Many successful
studies included sample sizes of 10 or more rodents, where usually 1-2 the rodents were
excluded due to inadequate exploration [74].
NOL, a task normally completed in combination with another task of memory such as
NOR is similar, except for the testing phase. In a study comparing NOR and NOL, testing of
wildtype mice using NOL, found that mice equally explored objects in the exploration phase,
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whereas in the testing phase, mice spent greater than 50% more time with the moved object than
the object that remained in the same space [68]. A study by Heyward et.al. used a diet- induced
obesity mouse model assessing cognitive deficits between control and diet- induced obesity
mice. The diet- induced obese mice spent significantly less time exploring the novel object when
compared to the control mice[75]. The concluding data from our study using the NOL task, like
the NOR task, found no differences between baseline STD and HFD mice. In conclusion, when
comparing our data with other studies, potential differences that negatively affected our ability to
see impairments could be the following: Sample size, our sample size was smaller than the
recommended sample size that would give us enough mice to exclude if needed. The ages of
mice used, in this study we chose to focus on older mice that had been on the diet longer and had
those more mature diet-induced cognitive deficits. Timing issues, the Claramine in the implanted
mini pump may have been potent for a shorter time period. Last, the length of time between
implanting the mini pump to the start of the cognitive tasks may not have been long enough as
implantation may cause an inflammatory response, which negatively impacts cognition. Both the
NOR and NOL tasks were completed days 3 and 4- post mini pump implantation. The STD mice
did not perform at the level expected which led to suspicions that there could be an inflammatory
response that affects our ability to observe differences [76]. When assessing insulin signaling
using tissue collected from these animals, we did not see changes in hippocampal PTP1B protein
levels, perhaps an assay to assess PTP1B activity could have been used to compare the activity
assessed compared to protein levels.
4.1 Future directions
Previous work in our lab was done measuring insulin receptor internalization in MBEC’s
using the EZ-Link™ Sulfo-NHS-SS-Biotin labelling kit and western blotting. This study
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concluded that when compared to naïve cells, there was a decrease in insulin receptor
internalization over time and decreased tyrosine phosphorylation in hyperinsulinemic cells.
Using the same methods, when compared to naïve cells, there was a decrease in internalized
insulin receptors in cells treated with S961, an insulin receptor antagonist, but when
hyperinsulinemic cells were treated with Claramine there was an increase of internalization
compared to hyperinsulinemic cells. Insulin can be internalized by the insulin- related IR present
on endothelial cells, a process known as receptor mediated endocytosis [77]. At the cellular
level, insulin binds to its receptor on the plasma membrane leading to a signaling cascade that
regulates metabolism and cell growth. The insulin bound IR internalizes via clathrin-mediated
endocytosis [78]. Insulin binding sites on brain endothelial cells have two functions transporting
insulin across the BBB and activating receptors such as signaling and insulin like growth factors
[77]. Future research will help us gain a better understanding of whether PTP1B inhibits insulin
receptor endocytosis. Using flow cytometry and what our research found about Claramine
inhibition of PTP1B, new research can investigate endocytosis of the insulin receptor. Cell
sorting of endosomes in naïve MBEC’s as well as hyperinsulinemic cells and hyperinsulinemic
cells treated with Claramine, will allow us to collect those endosomes to use for western blotting
to assess the insulin receptors that have been internalized via endocytosis.
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Abstract
Obesity, neurodegenerative diseases, and injury can all lead to cognitive deficits, which can be
improved clinically with the implementation of cognitive rehabilitation. Due to a lack of effective
cognitive rehabilitation tools in mice, we re-designed a cognitive task utilized to detect problemsolving deficits, to develop a cognitive rehabilitation paradigm for mice. In this study, we
developed a modified the Puzzle Box task by exposing B6 mice to a variety of obstacles and
assessing the escape latencies. We then combined obstacles in order to create a “complex obstacle”
for the problem-solving task. We determined that our task was reproducible in different cohorts of
mice. Furthermore, with repetition the mice display an improvement in the performance, evident
by a shorter escape latency and the ability to maintain this improvement in performance, indicative
of long-term memory. Given that this approach is new, we validated whether this task could
successful detect deficits in a mouse model of cognitive impairment, the high-fat diet mouse. We
demonstrate that high-fat diet mice have longer escape latencies when exposed to the complex
obstacle compared to standard diet control mice. Taken together, these data suggest that the Puzzle
Box is a valid task for cognitive rehabilitation in mice.

Keywords:
Behavioral task, cognitive impairment, light-dark box, memory, problem-solving, Puzzle Box

Abbreviations:
HFD, high fat diet; STD, standard diet; ANOVA, analysis of variance; LEGO Brdg, LEGO
Bridge.
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1. Introduction
Cognitive rehabilitation is a therapeutic process designed to improve cognitive function in
areas related to attention, memory, comprehension, problem-solving and awareness [79, 80].
Cognitive rehabilitation is divided into two components: restorative and compensatory. [79, 80].
The restorative approach reinforces, strengthens, and reestablishes previously learned patterns. On
the other hand, the compensatory approach enables adaptation to the deficit. For example, stroke
survivors experiencing a neurological disorder characterized by the inability to explore or respond
to external stimuli contralateral to the lesion, known as spatial neglect, undergo cognitive
rehabilitation to enhance visual perception to compensate for the spatial deficits [81]. Cognitive
rehabilitation improves cognitive function in older adults (>65 years and older) with cognitive
impairment [82]. Cognitive rehabilitation also improves cognition in disorders such as
schizophrenia [83-86], head injuries [87, 88], stroke [89, 90], and substance abuse [91].
Furthermore, preliminary results suggests that cognitive rehabilitation also improves cognitive
deficits associated with Alzheimer’s disease and Parkinson’s disease [92, 93].
Combining cognitive rehabilitation with a motor task may be useful for elderly to prevent falls,
in stroke survivors, and in individuals with traumatic brain injury [94]. Tasks that require more
cognitive effort are predicted to be more effective for motor learning [95]. Many of the current
cognitive tasks for mice are excellent at assessing cognitive function but may not be suitable for
cognitive rehabilitation in mice with motor impairments. For example, common cognitive tasks
such as the Morris Water Maze and radial arm maze, which assess learning and memory deficits,
require normal motor function. Hence, there is a need to develop a cognitive task that can be
achieved even with limited motor function.
The Puzzle Box was previously designed as a problem-solving task [70]. The Puzzle Box has
demonstrated consistency and effective for detecting cognitive deficits [70, 71, 96]. The purpose
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of this study was to modify the Puzzle Box to develop a reliable and valid cognitive rehabilitative
task for animals. The development of a cognitive rehabilitation task in mice can be useful to study
the benefits of cognitive rehabilitation in preclinical models of stroke, Alzheimer’s and
Parkinson’s disease. A good cognitive rehabilitation task must reveal an enhancement in
performance with repetition [79]. Furthermore, an effective cognitive rehabilitation task will lead
to retention of performance from day to day [80]. Thus, in this study we characterize the
development of a cognitive rehabilitation task for mice by modifying the Puzzle Box paradigm.
We also validated the ability of this modified Puzzle Box paradigm to detect cognitive impairment
in a mouse model of cognitive impairment, the high-fat diet (HFD) mouse.

2. Materials and Methods
2.1 Puzzle Box design
The Puzzle Box is a two-compartment arena consisting of an open field (12 x 10 inches) and a
covered/enclosed compartment (dark box) connected via a 1.5-inch escape door (Fig. 1A). The
arena was constructed using three 18 x 10 inches, three 10 x 10 inches, and one 6 x 10 inches
acrylic sheets. The dark box compartment was painted black (Rust- Oleum Professional). The
acrylic sheets were glued together with 2-part epoxy (Loctite plastic epoxy) and all spaces and
cracks were sealed with sealant (Lexel). Five different obstacles were placed in the open door zone
(Fig. 1A; red box, 4.25 x 4.25 inches) used to obstruct the escape door (Fig. 1B): 1) nestlet, which
is used by the mice as bedding in their home cages, was placed behind the escape door (Fig. 1C);
2) enviro-dri, which was placed in front of the escape door requiring the mouse to burrow through
or remove the enviro-dri (Fig. 1D); 3) LEGO bridge, which was placed in front of the escape door
requiring the mouse to either go over or under to enter the dark box (Fig. 1E); 4) LEGO stairs,
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which required the mouse to walk up and then down the stairs to enter the dark box (Fig. 1F); and
5) the tunnel is a T shaped tunnel giving the mouse three ways to enter the dark box (Fig. 1G).

2.2 Animals
Male and female C57BL6 mice (Jackson Laboratory, Bar Harbor, Maine) 6-24 months of age
fed a regular chow diet from Teklad were used for these studies. This age range was used to
establish baseline behavior in normal mice at ages typically used in preclinical models with
cognitive impairment. Mice were housed in a pathogen-free environment. All protocols were
approved by the Medical University of South Carolina Institutional Animal Care and Use
Committee, and are in compliance with the university guidelines, state and federal regulations, and
the standard of the “Guide for the Care and Use of Laboratory Animals”. The animal welfare
assurance number on file with the NIH Office of Laboratory Animal Welfare (OLAW) is A342801. The Medical University of South Carolina is accredited by the Association for the Assessment
and Accreditation of Laboratory Animal Care International (AAALAC, Intl.).

2.3 Development of problem-solving task
The problem-solving task was performed in the Puzzle Box as described above. A video
camera (Besteker HD) was mounted above the open field and Panlab Harvard Apparatus’s
SMART video tracking software (Barcelona, Spain) is used to record the movements of the mouse
and the escape latency from the open field to the dark box. The mice were allowed to explore the
empty Puzzle Box until they escaped to the dark box or for 300 seconds. Following three trials
with the open door, the escape latency with the nestlet, enviro-dri, LEGO bridge, LEGO stairs,
and tunnel trials were recorded. Three different complex obstacles were designed by combing 2-3
of the aforementioned obstacles: complex 1) LEGO stairs and nestlet; complex 2) LEGO bridge,
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enviro-dri, and nestlet; and complex 3) the tunnel, enviro-dri and nestlet. The mice were subjected
to three trials for each obstacle. The arena, LEGO and tunnel obstacles were thoroughly cleaned
with ethanol between each trial and mouse. Furthermore, fresh enviro-dri and nestlet were used
for each trial and mouse.

2.4 Validation in mouse model of cognitive impairment
To generate a mouse model of cognitive impairment, B6 mice purchased from Jackson
Laboratory (Bar Harbor, Maine) were placed on either the standard diet (STD) consisting of 10%
kcal from fat (Research Diets Inc.; #D12450B, New Brunswick, NJ) or a HFD with 54% kcal from
fat (Research Diets Inc.; D05090701) ad libitum at 4 weeks of age per our previously published
protocol [15, 97]. After 28 weeks of diet, both groups were subjected to the Puzzle Box and
performed 3 trials each of open door, 3 nestlet, enviro-dri and tunnel. In addition, the mice were
also subjected to 3 trials of the complex obstacle 3. Recording and tracking of the mice was done
according to the protocol above.

2.5 Statistical Analysis
Data analyses were performed using Prism v6 (GraphPad Software, Inc.). All sample sizes
represent the number of animals. All data were analyzed using either a one-way ANOVA with
Tukey’s Multiple Comparison Test (Evidence of learning for problem-solving the complex
obstacle and long-term memory retention for problem-solving the complex obstacle) or a mixedeffects repeated measures analysis with Bonferroni's multiple comparisons test (Validation of the
Puzzle Box: Problem-solving deficits in high-fat diet mice). All analyses significance was
determined using an alpha-level of 0.05.
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3. Results
3.1 Latency of individual obstacles
The escape latency of the third trial was evaluated, to establish the latency for each individual
obstacle (Fig. 1H; n=9). The shortest escape latency occurs with the open door (18.9 ±12.8
seconds) and the tunnel (21.8±13.8 seconds). The escape latency is approximately 4-5 times longer
with the nestlet (87.3±33.5 seconds), enviro-dri (73.1±45.1 seconds), LEGO bridge (69.5±24.9
seconds) compared with the open door. The longest escape latency occurs with LEGO stairs
(133.3±41.5 seconds).

3.2 Reproducibility of the Puzzle Box task
To investigate the reproducibility of the problem-solving task, the escape latency for 3 different
cohorts of mice following the third trial were evaluated (Fig. 1I; n=9). No significant differences
were found in the escape latencies between cohorts 1 (18.9±12.8 seconds), 2 (60.0±18.2 seconds),
and 3 (22.2±9.3 seconds) with the open door. Similarly, there were no significant differences in
the escape latencies for cohorts 1 (87.3±33.5 seconds), 2 (149.8±31.6 seconds) and 3 (155.2±26.6
seconds) with the nestlet. The escape latency for the enviro-dri was also similar among cohorts 1
(93.1±45 seconds), 2 (42.5±14.2 seconds), and 3 (64.9±18.2 seconds).

3.3 Correlation of escape latency with age
To investigate the correlation between escape latency and age, simple linear regression analysis
was performed (Fig. 1J). There was no correlation between escape latency and age with the open
door (F= 0.04; P= 0.836) and enviro-dri (F= 3.94; P= 0.058) obstacles. On the other hand, a
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significant correlation between escape latency and age was observed with the nestlet (F= 5.03; P=
0.034) obstacle.

3.4 Development of the cognitive rehabilitation task
3.4.1 Evidence of learning with the problem-solving task
To develop a problem-solving task, the escape latency for 3 trials in a subset of mice (cohort
2; n=9), were assessed using multiple obstacles combined to create 3 different complex obstacles.
For complex 1, the escape latency decreased by 70% from trial 1 (301.0 ± 85.61 seconds) to trial
2 (100.5 ± 30.03 seconds) and decreased 60% from trial 1 to trial 3 (130.0 ± 45.5 seconds) (Fig.
2A). For complex 2 (Fig. 2B), there were no significant differences among trial 1 (44.4 ± 10.3
seconds), trial 2 (41.6 ± 10.0 seconds), and trial 3 (35.2 ± 7.4 seconds). Finally, complex 3
consisting of the tunnel, enviro-dri and nestlet resulted in the most significant improvement in
subsequent trials (Fig. 2C), which led us to select complex 3 for subsequent analysis. There was a
90% decrease from trial 1 (1142.1±159.6 seconds) to trial 2 (156.5± 33.2 seconds) and from trial
2 to trial 3 (75.1± 16.2 seconds).

3.4.2 Evidence of retention with the problem-solving task
To assess retention for performance using complex 3, trials were performed using cohort 2
(n=9), 12 and 26 days later. The data reveals no significant differences at day 0 (75.1± 16.2
seconds), 12 (82.2± 11.6 seconds), and 26 (44.9± 13.2 seconds) (Fig. 2D).

3.5 Validation of problem-solving task using HFD mice
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To validate that the complex 3 obstacle detects cognitive deficits, the escape latencies were
assessed in STD (n=4) and HFD mice (n=11), a model of cognitive impairment, after three trials.
A mixed-effects repeated measures analysis revealed a significant effect of obstacle on escape
latency (F= 17.8; P= <0.0001). Analysis also revealed interaction effect between diet and obstacle
on escape latency (F= 5.4; P= 0.0010). There were no significant differences in the escape latencies
between STD versus HFD mice, for the open door (20.9± 6.5 versus 9.1± 1.4), nestlet (64.7± 25.4
versus 56.2± 21.8), enviro-dri (31.0± 8.0 versus 20.4± 3.3), and tunnel (19.7± 2.8 versus 12.6±
1.6). The escape latency in the HFD (201.6± 21.7) mice was increased by 115% compared with
the STD (93.7± 23.6) mice when completing complex 3. There was a significant interaction with
obstacles (individual and complex 3; F= 15.3); however, there was no significant interaction with
diet (STD and HFD; F= 0.5; Fig. 3A). To evaluate the potential impact of HFD on mobility, total
distance for mice was assessed in STD and HFD mice. There were no significant differences in
total distance between STD versus HFD mice for open door (191.5± 117.0 versus 30.9± 4.1),
nestlet (207.7 ± 95.4 versus 169.6 ± 53.9), enviro- dri (49.0± 14.4 versus 52.8± 11.9), tunnel (34.9±
10.4 versus 30.5± 5.6) and complex 3 (99.2± 52.6 versus 218.2± 36.7; Fig. 3B). To evaluate
potential differences in exploratory behavior, we assessed the time in the open door zone, which
corresponds to time exploring/ interacting with the obstacles.

There were no significant

differences between STD versus HFD mice the time spent interacting with, open door (6.2±1.3
versus 4.8± 1.3), nestlet (10.2± 4.2 versus 17.5± 4.6), enviro- dri (15.9± 3.8 versus 13.1± 2.2),
tunnel (12.6± 3.3 versus 7.1± 1.6) and complex 3 (65.8± 45.6 versus 34.4± 6.8; Fig. 3C).
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4. Discussion
Cognitive rehabilitation has been effective for improving attention, memory, and executive
function in patients with traumatic brain injury, stroke [79, 80, 83, 98]. Currently, there are no
established cognitive rehabilitation paradigms for preclinical models. We provide for the first-time
evidence for the use of the Puzzle Box as a cognitive rehabilitation task. Similar to the initial
Puzzle Box design described by Ben Abdallah et al [71], our arena was made of Plexiglas with an
open field and a dark box connected by an escape door. In our study, we used objects to obstruct
the door that closely resembled objects used in previous studies [71, 96, 99]. On average the escape
latency in our study is comparable to those observed in other Puzzle Box studies [71, 99].
Furthermore, similar escape latencies among three different cohorts of mice for the open door,
nestlet, and enviro-dri suggests that the escape latencies are consistent among three cohorts of
mice.
In order for the Puzzle Box to be a viable cognitive rehabilitation task, there must be evidence
of improvement with repetition, indicative of learning [99] and the ability to retain this
improvement long-term. We demonstrated that the escape latency decreases between consecutive
trials. This suggests that the animals learn, evident by the enhancement in performance with
repetition when completing the problem-solving task. Furthermore, the mice retained this
enhancement of performance 12 and 26 days after the initial trial. Overall, this data suggests that
this modified version of the Puzzle Box may a useful paradigm for cognitive rehabilitation in mice.
Finally, in order to validate that this modified version of the Puzzle Box is capable of detecting
cognitive deficits, we performed the task in a mouse model of cognitive impairment, the HFD
mouse model. We previously demonstrated that cognitive impairment is evident in HFD mice by
28 weeks of age using both novel object recognition test and Morris Water Maze [15, 100]. While
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there appears to be no differences in the escape latencies between STD and HFD mice with the
open door, HFD mice demonstrate a significant increase in escape latency with the complex
obstacle. This data suggests that HFD mice have deficits in problem-solving. Previous tasks such
as the novel object recognition task and the Morris water maze detect deficits in recognition and
working memory, respectively. On the other hand, the Puzzle Box task detects problem-solving
deficits [101]. The advantage of using the Puzzle Box is that it can be potentially used for
rehabilitation. Interestingly, a previous study revealed that consumption of “good fats”, omega-3polyunsaturated fatty acids-enriched, formula can improve problem-solving abilities in 9 month
old babies [102]. Our previous studies demonstrates that HFD mice spend similar amounts of time
exploring during object recognition tasks [15, 100]. Our current data reveals that the distance
traveled by the STD and HFD mice are comparable, suggesting that diet does not impact mobility.
Furthermore, STD and HFD mice spend similar amounts of time interacting with obstacles and in
the open field, which indicates that diet does not affect the motivation to explore. Thus, in addition
to memory deficits previously reported [15, 100], our data suggests that HFD also contributes to
impairments with problem-solving.
In summary, we have demonstrated that the Puzzle Box can be modified for cognitive
rehabilitation training. Our data reveals that the Puzzle Box task is reproducible among various
cohorts of mice. Furthermore, we demonstrate that mice display an enhancement in performance
evident by the decrease in escape latency with repetition. The enhancement in performance is
retained for several days suggesting that the tasks augments long-term memory. We also observed
problem-solving deficits in a mouse model of cognitive impairment, the HFD mouse. We conclude
that the Puzzle Box is a useful task for assessing cognitive impairment and can be used as a
cognitive rehabilitation task in mice.
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Figure 1. Puzzle box design, escape latency for individual obstacles and reproducibility of
the Puzzle Box. (A) The top view of the puzzle box arena. The puzzle box consists of an open
field (*) connected by an (B) open door (black arrow) to a dark box (◊). The open door zone (red
box) is obstructed with either (C) the nestlet, (D) enviro-dri, (E) LEGO bridge and (F) LEGO
stairs and a (G) tunnel. (H) Escape latency in seconds (sec) with open door, nestlet, enviro-dri,
LEGO Bridge (LEGO Brdg), LEGO stairs, and tunnel. (I) Reproducibility of the escape latency
in sec for the open door, nestlet, and enviro-dri for 3 different cohorts of mice. White, grey and
black bars represent cohort 1, 2, and 3, respectively. (J) Correlation of escape latencies (sec) and
48

age (months) with open door (open circles and solid black line), nestlet (black squares and
dashed line) and enviro- dri (grey triangles and black dotted line) in cohort 1, 2, and 3. Data
represents mean ± SEM; n=9 per group; *P≤ 0.05.
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Figure 2. Evidence of learning for problem-solving the complex obstacle and long-term
memory retention for problem-solving the complex obstacle. Escape latency in seconds (sec)
during 3 consecutive trials with (A) complex 1 obstacle, which consists of LEGO stairs and
nestlet; (B) complex 2 obstacle, which consists of the LEGO bridge, enviro- dri and nestlet; (C)
complex 3 obstacle, which consists of the tunnel, enviro- dri, and the nestlet; Repeated measures
one-way ANOVA and Tukey’s post-hoc used for multiple comparisons. (D) Escape latency in
sec at 0, 12, and 26 days with complex 3 obstacle; Ordinary one-way ANOVA and Tukey’s posthoc used for multiple comparisons. Data represents mean ± SEM; n=9; * P ≤ 0.05; *** P≤ 0.001;
not significant (NS).
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Figure 3. Validation of the Puzzle Box: Problem-solving deficits in high-fat diet mice. The
(A) escape latency (seconds; sec), (B) total distance (centimeters; cm), (C) time (sec) interacting
within the open door zone indicative of exploratory behavior in both standard diet (STD; white
bars) and high-fat diet (HFD; black bars) mice with individual obstacles and the complex 1
obstacle. Data represents mean ± SEM; n=4 (STD) and n=11 (HFD); *P≤ 0.05. A mixed-effects
repeated measures analysis with Bonferroni's multiple comparisons test used for analysis.
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